Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Kouvatseas, G. | en |
dc.contributor.author | Pagdatoglou, K. | en |
dc.contributor.author | Palamidas, F. | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Angelidou, M. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Samantas, E. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Kouvatseas, G. | en |
dc.creator | Pagdatoglou, K. | en |
dc.creator | Palamidas, F. | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Angelidou, M. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.date.accessioned | 2018-06-22T09:52:47Z | |
dc.date.available | 2018-06-22T09:52:47Z | |
dc.date.issued | 2002 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41503 | |
dc.description.abstract | Background: Prognostic factors among Greek patients with SCLC were evaluated. Patients and Methods: Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis was performed. Results: Complete response (CR) was achieved in 26,8% and partial response in 40.1% of patients. The median duration of response was 7.4 months, the median survival 10.5 months and the 2-year survival rate 12%. The stage of the disease was a dominant prognostic factor for survival and response. PS 0-1 was a major prognostic factor for survival, duration of response and CR. Female gender was a favorable predictor for CR. Superior vena cava syndrome was a poor prognostic factor for survival and duration of response. Weight loss and age ≥60 were poor predictors for response. The sites of metastases affected survival, duration of response and response. Normal alkaline phosphatase was a favorable prognostic factor for survival, duration of response and response. Normal lactate dehydrogenase and thoracic irradiation were favorable prognostic factors for survival and duration of response. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Greece | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cisplatin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Neoplasm staging | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Survival rate | en |
dc.subject | Treatment outcome | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung small cell cancer | en |
dc.subject | Multivariate analysis | en |
dc.subject | Survival | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Epirubicin | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Risk factors | en |
dc.subject | Sex difference | en |
dc.subject | Prognostic factors | en |
dc.subject | Weight reduction | en |
dc.subject | Ifosfamide | en |
dc.subject | Small cell | en |
dc.subject | Superior cava vein syndrome | en |
dc.subject | Superior vena cava syndrome | en |
dc.subject | Clinical trials | en |
dc.subject | Sex factors | en |
dc.subject | Aging | en |
dc.subject | Duration of response | en |
dc.subject | Ethnic groups | en |
dc.subject | Extensive disease | en |
dc.subject | Limited disease | en |
dc.subject | Multimodality cancer therapy | en |
dc.subject | Reponse | en |
dc.subject | Small cell lung cancer | en |
dc.title | Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 22 | |
dc.description.issue | 6 B | en |
dc.description.startingpage | 3749 | |
dc.description.endingpage | 3757 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-3286-778X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |